Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
Completed
AstraZeneca
Phase 3
2002-04-01
This is a randomized, triple-blind, placebo-controlled, multicenter study to investigate the
safety of pramlintide treatment using pramlintide dose-titration coupled with insulin
adjustments in subjects with type 1 diabetes who are actively trying to improve their
glycemic control.
This is a randomized, open-label, crossover study to examine the bioavailability of
pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus
using insulin.
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
Completed
AstraZeneca
Phase 2
2002-07-01
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over
study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and
obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide
Completed
AstraZeneca
Phase 2
2002-08-01
This is a randomized, single-blind, placebo-controlled, crossover study to examine the effect
of pramlintide on the pharmacokinetics of an orally administered medication
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
Completed
AstraZeneca
Phase 3
2002-11-01
This is a multicenter, open-label extension study designed to examine the long-term safety of
pramlintide treatment in subjects with type 1 diabetes who have successfully completed
treatment in the parent study 137-150.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
